Consensus Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 07:00:03 17/10/26 am AEDT			5-day change	1st Jan Change
118.28 ^USD	-2.48%		-0.35%	+47.57%

09/10	Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating	MT
09/10	CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform	MT

Evolution of the Average Target: Haemonetics Corporation

Evolution of the Target Price: Haemonetics Corporation

Changes in Analyst Recommendations: Haemonetics Corporation

771ec1a0cf97b.TNonR96vLN2XKiinAZu05OHbuYu-jT45cV_I9cIoGq0.E-5EHe3XdKrxWlzqea_5gpWMj8Xh50pyFS-8v5R_V-Yk93UfiuABrs97Ww~f2cc5214a8410a172e62102f165df627

Analysts' recommendations: Haemonetics Corporation

09/10	Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating	MT
18/09	Haemonetics Shares Rise After Citigroup Upgrade	MT
17/09	Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92	MT
19/08	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
13/08	BofA Securities Adjusts Price Target on Haemonetics to $100 From $93	MT
12/08	BofA Securities Adjusts Haemonetics Price Target to $100 From $93	MT
07/08	Barrington Research Adjusts Haemonetics PT to $95 From $89, Maintains Outperform Rating	MT
23/05	Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says	MT
22/05	BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80	MT
12/05	Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating	MT
13/01	Barrington Adjusts Price Target on Haemonetics to $93 From $90, Maintains Outperform Rating	MT
15/12	Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target	MT
12/12	Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77	MT
08/11	Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says	MT
08/11	BofA Securities Upgrades Haemonetics to Neutral From Underperform, Raises Price Target to $75 From $58	MT
08/11	Needham Raises Price Target on Haemonetics to $78 From $68, Keeps Buy Rating	MT
12/08/25	Haemonetics Shares Fall After Raymond James Downgrade	MT
11/08/25	Raymond James Downgrades Haemonetics to Outperform From Strong Buy	MT
09/08/25	Haemonetics Shares Fall After JPMorgan Downgrade	MT
08/08/25	Needham Cuts Price Target on Haemonetics to $68 From $84, Keeps Buy Rating	MT
08/08/25	JPMorgan Downgrades Haemonetics to Neutral From Overweight, Adjusts Price Target to $62 From $85	MT
10/07/25	Haemonetics Shares Rise After Upgrade From Citigroup	MT
09/07/25	Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71	MT
09/07/25	Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…
26/06/25	Baird Initiates Coverage on Haemonetics With Outperform Rating, $87 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HAEMONETICS CORPORATION					+5.26%
	ABBOTT LABORATORIES					+15.09%
	MEDTRONIC PLC					+10.41%
	STRYKER CORPORATION					+23.06%
	ESSILORLUXOTTICA					+43.42%
	CENCORA, INC.					+7.85%
	HOYA CORPORATION					+16.96%
	BECTON, DICKINSON AND COMPANY					+1.21%
	IDEXX LABORATORIES, INC.					+25.9%
	DEXCOM, INC.					+12.11%
	Average					+16.13%
	Weighted average by Cap.					+17.58%